These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15106540)

  • 1. The dream of a do-it-all "polypill". The reality: patients will probably keep taking separate heart drugs.
    Heart Advis; 2003 Oct; 6(10):1, 7. PubMed ID: 15106540
    [No Abstract]   [Full Text] [Related]  

  • 2. The Polypill: a simple "cure" for heart disease and stroke?
    Harv Mens Health Watch; 2004 Mar; 8(8):6-7. PubMed ID: 15044123
    [No Abstract]   [Full Text] [Related]  

  • 3. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Disease Prevention at a Crossroads:: Precision Medicine or Polypill?
    Joyner MJ; Paneth N
    JAMA; 2019 Dec; 322(23):2281-2282. PubMed ID: 31764938
    [No Abstract]   [Full Text] [Related]  

  • 6. A single pill for prevention?
    Harv Heart Lett; 2009 Jul; 19(11):6. PubMed ID: 19927382
    [No Abstract]   [Full Text] [Related]  

  • 7. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 8. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A "polypill" a day keeps heart disease away.
    Health News; 2003 Sep; 9(9):5. PubMed ID: 14584468
    [No Abstract]   [Full Text] [Related]  

  • 10. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 11. Polypill remains the only panacea in sight for cardiovascular disease, trial organiser says.
    Hawkes N
    BMJ; 2012 Jul; 345():e4837. PubMed ID: 22807080
    [No Abstract]   [Full Text] [Related]  

  • 12. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
    Malekzadeh F; Marshall T; Pourshams A; Gharravi M; Aslani A; Nateghi A; Rastegarpanah M; Khoshnia M; Semnani S; Salahi R; Thomas GN; Larijani B; Cheng KK; Malekzadeh R
    Int J Clin Pract; 2010 Aug; 64(9):1220-7. PubMed ID: 20653798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polypill.
    Drown DJ
    Prog Cardiovasc Nurs; 2003; 18(4):197. PubMed ID: 14605522
    [No Abstract]   [Full Text] [Related]  

  • 14. Implementation Strategies for Cardiovascular Polypills.
    Huffman MD; Salam A; Patel A
    JAMA; 2019 Dec; 322(23):2279-2280. PubMed ID: 31764946
    [No Abstract]   [Full Text] [Related]  

  • 15. The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera.
    Franco OH; Karnik K; Bonneux L
    Horm Metab Res; 2007 Sep; 39(9):627-31. PubMed ID: 17846968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Polypill - A Practicable Approach?].
    Thürmann PA; Kleinerüschkamp AG; Boehme P
    Dtsch Med Wochenschr; 2019 Jun; 144(11):715-718. PubMed ID: 31163467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polypill to prevent cardiovascular disease: physicians' perspectives.
    Viera AJ
    Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.